Market Access

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

PwC projects drug spending will outpace medical trends in 2027, driven by GLP-1s and oncology. Here's what it means for market access.

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, FDA expands OTC naloxone, and DSV launches a new pharma air route.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

A new BGH survey shows some large employers are pulling back on GLP-1 weight-loss coverage in 2027 as rising costs and utilization outpace anticipated savings.

In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche commit billions to protein degrader platforms, and more.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

USP's Annual Drug Shortages Report reveals a sharp rise in product discontinuations, driven by unsustainable generic pricing, upstream geographic concentration, and manufacturing complexity.

After adding 160 more drugs, TrumpRx tops 800 prescription offerings. Here's what the latest MFN-driven expansion means for pricing and access.

A new CMS demonstration launching July 1 will offer eligible Part D beneficiaries access to branded obesity drugs at a $50 copay. Here's what manufacturers, payers, and pharmacies need to know.

Novo Nordisk's UAE launch of the Wegovy pill signals a new phase of oral GLP-1 commercialization, with major implications for pharma distribution, channel strategy, and international market access.

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Cencora will support US distribution of Kite's Yescarta and Tecartus, reducing administrative burdens and expanding CAR T-cell therapy access at authorized treatment centers.

Cameron Olig explains how transparency and direct access models can help pharma close the gap between drug pricing, distribution and the patient.

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.